Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Immune cells with a killer instinct: Tried-and-tested anti-tumor drug displays new effect

26.03.2012
Imiquimod, a drug used to treat skin cancer, has been shown to have a previously unknown effect on immune cells. The drug transforms cells known as dendritic cells into "tumour killers" that attack the tumour directly and destroy its cells.

The dendritic cells adopt an ingenious approach here - they not only produce special substances with a cell-damaging effect, they also manage to fight the tumour without the help of T and B cells and natural killer (NK) cells. This complex interaction was discovered by scientists participating in a doctoral programme of the Austrian Science Fund FWF. It was also recently published and commented on in the Journal of Clinical Investigation.

For 15 years now the drug Imiquimod has been authorised for the treatment of certain skin diseases, including some types of skin cancer. And during that period, the drug, which is administered as a skin cream, has proven to be an effective treatment. Despite this therapeutic success, the drug´s exact mechanism of action was not known to date. However, a research group working with Prof. Maria Sibilia, Head of the Institute for Cancer Research at the Medical University of Vienna, has now succeeded in determining some unknown and surprising effects of Imiquimod (Imi) on special immune cells.

CELLULAR INFANTRY
In a mouse model for malignant melanoma, Prof. Sibilia and her team succeeded in demonstrating that Imiquimod not only triggers the "recruitment" of special immune cells, but also "arms" them for the battle against tumour cells. "We were able to show that Imi has an immediate and direct effect on mast cells in the skin. Mast cells are immune system cells that can release messenger substances for the control of an immune response. In reaction to Imi, which activates special receptors known as toll-like receptors, mast cells release CCL2 messenger substances - a starting signal that triggers a response with fatal consequences for tumour cells," explains Dr. Barbara Drobits, key scientist in the FWF-funded doctoral programme responsible for the discovery.

The group actually succeeded in demonstrating that CCL2 then causes the migration of additional immune system cells. The analysis of the subsequent activity of these immune cells generated a real surprise for the scientists: the immune cells, called plasmacytoid dendritic cells (pDCs), were considered to be modulators up to now. However, in their reaction to Imi, they proved to be bona fide aggressors.

FIGHTING STRATEGY
Prof. Sibilia reports: "My team succeeded in decoding an important aspect of the mechanism of action triggered by Imiquimod and the role of the pDCs in this process. This is part of a complex strategy adopted by the body in the fight against tumours. pDCs were not only attracted by CCL2, but were also prompted to produce interferon alpha (IFN alpha) in response Imi." IFN alpha actually triggers the production of different substances (TRAIL, granzyme B) that can have a fatal effect on tumour cells. As another special characteristic, it was possible to show, for the first time, that pDCs themselves initiate the destruction of the tumour cells independent of the immune cells of the adaptive immune system (B and T cells) and without the help of NK cells, both of which are considered important components of the anti-tumoural immune response.

Overall, the team from the doctoral programme "Inflammation and Immunity" succeeded in discovering a new mechanism of action of dendritic cells in fighting tumours; it had never been possible before to observe such a direct attack on tumours by pDCs. Further studies will reveal the extent to which this discovery will benefit the development of innovative cancer therapies. Some important questions remain open, however, as Dr. Drobits explains: "It is known that some tumour cells produce CCL2 themselves. In other words, they should have triggered the same cascade as Imi. But this did not always result in a positive disease progression. We do not yet know why this is the case and it needs to be explained." In meeting challenges like this, the FWF´s doctoral programme once again proves that it is fulfilling an important goal: to give young scientists the opportunity to work at the vanguard of cutting-edge science.

Original publication: Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. B. Drobits, M. Holcmann, N. Amberg, M. Swiecki, R. Grundtner, M. Hammer, M. Colonna, and M. Sibilia. J Clin Invest. 2012;122(2):575 585. doi:10.1172/JCI61034.

Picture and text available from Monday, March 26 2012, 9 am CET at:
http://www.fwf.ac.at/en/public_relations/press/pv201203-en.html
Scientific Contact:
Prof. Maria Sibilia
Institute for Cancer Research
Medical University Vienna
Borschkegasse 8a
1090 Vienna, Austria
T +43 / (0)1 / 4277 65211
E Maria.Sibilia@meduniwien.ac.at
Austrian Science Fund FWF:
Mag. Stefan Bernhardt
Haus der Forschung
Sensengasse 1
1090 Vienna, Austria
T +43 / (0)1 / 505 67 40 - 8111
E stefan.bernhardt@fwf.ac.at
W http://www.fwf.ac.at
Copy Editing & Distribution:
PR&D - Public Relations for Research and Education Mariannengasse 8
1090 Vienna, Austria
T +43 / (0)1 / 505 70 44
E contact@prd.at
W http://www.prd.at

Stefan Bernhardt | PR&D
Further information:
http://www.fwf.ac.at

More articles from Life Sciences:

nachricht Helping to Transport Proteins Inside the Cell
21.11.2018 | Albert-Ludwigs-Universität Freiburg im Breisgau

nachricht UNH researchers create a more effective hydrogel for healing wounds
21.11.2018 | University of New Hampshire

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First diode for magnetic fields

Innsbruck quantum physicists have constructed a diode for magnetic fields and then tested it in the laboratory. The device, developed by the research groups led by the theorist Oriol Romero-Isart and the experimental physicist Gerhard Kirchmair, could open up a number of new applications.

Electric diodes are essential electronic components that conduct electricity in one direction but prevent conduction in the opposite one. They are found at the...

Im Focus: Nonstop Tranport of Cargo in Nanomachines

Max Planck researchers revel the nano-structure of molecular trains and the reason for smooth transport in cellular antennas.

Moving around, sensing the extracellular environment, and signaling to other cells are important for a cell to function properly. Responsible for those tasks...

Im Focus: UNH scientists help provide first-ever views of elusive energy explosion

Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.

Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Optical Coherence Tomography: German-Japanese Research Alliance hosted Medical Imaging Conference

19.11.2018 | Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

 
Latest News

Helping to Transport Proteins Inside the Cell

21.11.2018 | Life Sciences

Meta-surface corrects for chromatic aberrations across all kinds of lenses

21.11.2018 | Power and Electrical Engineering

Removing toxic mercury from contaminated water

21.11.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>